{"publication_id":"465c8fd4-570f-4fb2-9b87-1059b5787f6b","screening":{"identified":12,"screened":12,"excluded":0,"included":12,"included_or_retained":12,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that vitamin k2 vascular aging should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The curated corpus for vitamin K2 and vascular aging draws from 12 reference papers, but this body of evidence is distinguished by the near-complete absence of long-duration, hard-endpoint randomized controlled trials. No source in this corpus reports a prospective RCT designed to assess the effect of menaquinone-7 supplementation on a primary endpoint of major adverse cardiovascular events, all-cause mortality, or clinical fracture. This creates a structural gap: the headline conclusions about vitamin K2's role in vascular aging must rely on biomarker and surrogacy endpoints that may not translate to clinical benefit, a well-documented limitation in cardiovascular research that cautions against assuming surrogate validity (Ioannidis 2005). The absence of a definitive mortality or morbidity RCT in this corpus means the claim that vitamin K2 reduces cardiovascular risk in aging adults remains speculative and cannot be confirmed or refuted from the evidence currently at hand. Future work requires multi-year, event-driven trials explicitly designed to close this gap.","Endpoint scope represents a further limitation of this evidence base. The synthesis addresses vascular aging, but the corpus contains no source that directly measures arterial age, biological age acceleration, or validated composite aging scores. Zhao 2024's systematic review and meta-analysis of vitamin K supplementation reported pooled weighted mean differences for cardiovascular risk factors, but the constituent studies measured intermediate markers—such as pulse wave velocity, carotid intima-media thickness, and uncarboxylated matrix Gla protein—rather than validated aging endpoints. Furthermore, hard clinical endpoints such as myocardial infarction, stroke, and all-cause mortality are entirely absent from the interventional evidence; only Palamar 2025 provides descriptive mortality data from a CKD observational context, which does not test a vitamin K2 intervention. The mechanism-to-clinic gap is also notable: animal-model and in-vitro mechanistic evidence from Xu 2025 suggests bisphosphonates may reduce vascular calcium content, but translating mechanistic plausibility from bisphosphonate research to vitamin K2 supplementation requires human trial confirmation that this corpus does not provide. The synthesis therefore cannot determine whether vitamin K2 modifies the trajectory of vascular aging in humans, only that mechanistic and observational signals exist and that intervention-level evidence remains too sparse and too short-term to resolve the question.","For vitamin k2 vascular aging, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support vitamin k2 vascular aging as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 12 curated reference papers, the evidence base for Vitamin K2 vascular aging shows a context-dependent profile. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Vitamin K2 vascular aging anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}